Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Ensuring A Bright Future For The EU Orphan Medicines Regime

This article was originally published in SRA

Executive Summary

Since the EU orphan medicines regime was established in April 2000, it has resulted in around 1,600 orphan medicine designations and more than 120 marketing authorizations for orphan medicines. Now, though, some of the key principles governing the criteria and procedure for orphan designation are being reviewed, and it is important that all stakeholders contribute to the ongoing consultation to help ensure a robust regime for the future, says Peter Bogaert.

Advertisement
Advertisement
UsernamePublicRestriction

Register